Veves A, Falanga V, Armstrong DG, et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. .Diabetes Care 24::290. ,2001. .
Gentzkow GD, Iwasaki SD, Hershon KS, et al: Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. .Diabetes Care 19::350. ,1996. .
Armstrong DG, Lavery LA, Abu Rumman PL, et al: Outcomes of topical vacuum on wounds of the diabetic foot. .Ostomy Wound Manage 48::64. ,2002. .
Schneider AM, Morykwas MJ, Argenta LC: A new and reliable method of securing skin grafts to the difficult recipient bed. .Plast Reconstr Surg 102::1195. ,1998. .
Genecov DG, Schneider AM, Morykwas MJ, et al: A controlled subatmospheric pressure dressing increases the rate of skin graft donor site reepithelialization. .Ann Plast Surg 40::219. ,1998. .
The use of bioengineered tissue and topical subatmospheric pressure therapy have both been widely accepted as adjunctive therapies for the treatment of noninfected, nonischemic diabetic foot wounds. This article describes a temporally overlapping method of care that includes a period of simultaneous application of bioengineered tissue (Apligraf, Novartis Pharmaceuticals Corp, East Hanover, New Jersey) and subatmospheric pressure therapy delivered through the VAC (Vacuum Assisted Closure) system (KCI, Inc, San Antonio, Texas). Future descriptive and analytic works may test the hypothesis that combined therapies used at different and often overlapping periods during the wound-healing cycle may be more effective than a single modality. (J Am Podiatr Med Assoc 92(7): 395-397, 2002)